A5028533451- HIV/AIDS Research and Interventions
- HIV/AIDS drug development and treatment
- HIV Research and Treatment
- HIV-related health complications and treatments
- Mobile Health and mHealth Applications
- Privacy, Security, and Data Protection
- Innovative Teaching and Learning Methods
- Reflective Practices in Education
- Digital Mental Health Interventions
- Educational Strategies and Epistemologies
- Blood groups and transfusion
- FinTech, Crowdfunding, Digital Finance
- HIV, Drug Use, Sexual Risk
- Neuroscience and Music Perception
- Cytomegalovirus and herpesvirus research
University of Colorado Anschutz Medical Campus
2018-2025
University of Montana
2024-2025
University of Colorado Denver
2018-2022
Metropolitan State University of Denver
2017
Abstract Background Although tenofovir diphosphate (TFV-DP) in dried blood spots (DBS) is a predictor of adherence and pre-exposure prophylaxis efficacy, its utility human immunodeficiency virus (HIV) treatment remains unknown. Methods DBS for TFV-DP were collected up to 3 times over 48 weeks persons living with HIV (PLWH) who receiving TFV disoproxil fumarate (TDF)-based therapy. Log-transformed baseline was compared using t-tests or analyses variance; generalized estimating equations used...
Abstract Background Tenofovir diphosphate (TFV-DP) in dried blood spots (DBS) is associated with viral suppression persons living HIV (PLWH) taking tenofovir disoproxil fumarate (TDF). However, its value as a predictor of future viremia remained unknown. Methods Blood for plasma load (VL) and TFV-DP DBS were collected (up to 3 visits within 48 weeks) PLWH on TDF. cut points selected using logistic prediction models maximizing the area under receiver operation characteristic curve, estimated...
Previous studies have primarily focused on nucleos(t)ide reverse transcriptase inhibitor pharmacology in peripheral blood mononuclear cells (PBMCs) and erythrocytes via dried spots (DBS), but not other major cells. Our objectives were to describe compare the concentrations of tenofovir-diphosphate (TFV-DP) emtricitabine-triphosphate (FTC-TP) DBS, PBMCs, neutrophils, platelets people with HIV (PWH) without (PWOH). isolated from whole drawn PWH PWOH receiving tenofovir alafenamide...
Abstract Background QUANTI-TAF aimed to establish tenofovir-diphosphate (TFV-DP)/emtricitabine-triphosphate (FTC-TP) adherence benchmarks in dried blood spots (DBS) for persons with human immunodeficiency virus (PWH) receiving tenofovir alafenamide/emtricitabine (TAF/FTC)–based antiretroviral therapy (ART). Methods For 16 weeks, PWH received TAF/FTC-based ART co-encapsulated an ingestible sensor directly measure cumulative (enrollment final visit) and 10-day adherence. At monthly visits,...
The drivers of low-level viremia (LLV) between 20 and 200 copies/mL remain unclear. In 1042 person-visits from 497 persons with HIV on tenofovir disoproxil fumarate-containing antiretroviral therapy (ART), the association LLV cumulative adherence (quantified using diphosphate [TFV-DP] in dried blood spots) was assessed. Lower TFV-DP levels were associated higher odds LLV. As (fmol/punch) categories decreased >1650 to 800-1650; 800-1650 <800; <800, adjusted ratios for vs VL <20 2.0 (95% CI,...
Tenofovir diphosphate (TFV-DP) in dried blood spots (DBS) is a strong predictor of viral suppression persons living with HIV (PLWH). Its association antiretroviral therapy (ART) resistance remains unknown.Blood was collected PLWH receiving TDF-containing ART enrolled 48-week study. diphosphate/emtricitabine triphosphate (FTC-TP) were quantified from the same sample as load (VL) who developed within ≤12 months.The study 807 participants, whom 10 had new resistance-conferring mutations. Among...
To determine factors associated with interindividual variability in tenofovir diphosphate (TFV-DP) concentrations dried blood spots (DBSs) among persons living HIV (PLWH).PLWH who were at least 18 years old and taking disoproxil fumarate-containing ART prospectively recruited enrolled from a clinical cohort followed longitudinally (up to three visits over 48 weeks). With log-transformed TFV-DP DBSs as the outcome, mixed-model regression analyses used assess associations between self-reported...
Emtricitabine triphosphate (FTC-TP), the phosphorylated anabolite of emtricitabine, can be quantified in dried blood spots (DBS). We evaluated FTC-TP DBS as a predictor viral suppression and self-reported adherence FTC-TP. Persons living with HIV (PLWH) on an FTC-containing regimen were prospectively recruited. A load obtained during routine clinical visits. Self-reported for 3 days, 30 days months was captured. Generalized estimating equations used to estimate adjusted odds ratio (aOR)...
We investigated the effects of using experiential learning and direct instruction to teach metacognitive theory determine whether instructional type differentially affected higher vs. lower level learning. randomly assigned 87 introductory psychology students either or conditions. pretested participant’s knowledge theory, then participants received instruction, after which they completed a posttest theory. After covarying prior knowledge, data suggested that may be more effective than for...
Objective: Emtricitabine triphosphate (FTC-TP) in dried blood spots (DBS), a measure of short-term antiretroviral therapy (ART) adherence, is associated with viral suppression persons HIV (PWH). However, its ability to predict future viremia remains unknown. Design: Prospective, observational cohort (up three visits 48 weeks). Methods: PWH receiving TDF/FTC-based ART had DBS and load obtained at routine clinical visits. FTC-TP was dichotomized into quantifiable vs. below the limit...
Objective: People living with HIV (PLWH) are longer and developing more non-AIDS comorbidities, which negatively impact antiretroviral therapy (ART) adherence. Tenofovir diphosphate (TFV-DP) in dried blood spots (DBS) is a novel pharmacologic measure of cumulative ART adherence that predictive viral suppression future viremia. However, the relationship between comorbidities this unknown. We aimed to evaluate association 3 (diabetes mellitus (DM), hypertension, hyperlipidemia) TFV-DP DBS...
The adherence biomarker tenofovir diphosphate (TFV-DP) in dried blood spots (DBS) is associated with viral suppression and predicts future viremia. However, its association social determinants of health (SDoH) people human immunodeficiency virus (PWH) remains unknown. Dried for TFV-DP were longitudinally collected from a clinical cohort PWH receiving disoproxil fumarate-based therapy (up to 3 visits over 48 weeks) residing 5 Colorado counties. To assign SDoH, zip codes at enrollment matched...
Background Digital pill systems (DPSs), which comprise ingestible radiofrequency sensors integrated into a gelatin capsule that overencapsulates medication, can directly measure ingestion events. Objective Teaching users to operate DPS is vital ensure the collection of actionable and adherence data. In this study, we aim develop pilot training program, grounded in Technology Acceptance Model, instruct individuals on operation. Methods A two-part comprising in-person text message–based...
Abstract Background In this study, we evaluate associations between cumulative antiretroviral adherence/exposure, quantified using tenofovir diphosphate (TFV-DP) in dried blood spots (DBS), and human immunodeficiency virus (HIV)-related aging factors. Methods This is a cross-sectional analysis of younger (ages 18–35) older ≥60) persons with HIV (PWH) taking TFV disoproxil fumarate. Tenofovir concentrations were DBS. Linear logistic regression models used to TFV-DP bone mineral density (BMD),...
Variable adherence to antiretroviral therapy (ART) can maintain HIV viral suppression, but our understanding of the ART continuum remains limited. In a clinical cohort adult persons living with treated tenofovir (TFV) disoproxil fumarate/emtricitabine (TDF/FTC)-based regimen, data on 3-month self-reported and dried blood spots (DBS) for TFV diphosphate (TFV-DP) FTC triphosphate (FTC-TP) were collected. Among 521 participants in whom DBS available upon enrollment, 333 virologically suppressed...
To assess the association between tenofovir diphosphate (TFV-DP) in dried blood spots (DBS), a measure of cumulative tenofovir-based antiretroviral (ART) adherence, with medication regimen complexity persons human immunodeficiency virus (PWH).Prospective clinical cohort (up to three visits over 48 weeks).Academic-based HIV clinic.PWH receiving disoproxil fumarate (TDF)-based ART.DBS for TFV-DP were collected at every study visit. Baseline patient-level index (pMRCI) scores calculated and...
We assessed cumulative antiretroviral exposure-using tenofovir diphosphate (TFV-DP) in dried blood spots (DBS)-in persons with HIV (PWH) receiving disoproxil fumarate (TDF)-based therapy (ART) as single-tablet regimens (STR) or multiple-tablet (MTR).Blood for DBS was prospectively collected PWH on TDF during 1144 person visits (n = 523). Linear mixed-effects models, adjusted baseline characteristics, were used to compare TFV-DP STR versus MTR. Models ART regimen using either anchor drug...
<sec> <title>BACKGROUND</title> Digital pill systems (DPSs), which comprise ingestible radiofrequency sensors integrated into a gelatin capsule that overencapsulates medication, can directly measure ingestion events. </sec> <title>OBJECTIVE</title> Teaching users to operate DPS is vital ensure the collection of actionable and adherence data. In this study, we aim develop pilot training program, grounded in Technology Acceptance Model, instruct individuals on operation. <title>METHODS</title>...
The potency of modern antiretroviral therapy (ART) allows for greater forgiveness to missed doses while still achieving, and maintaining, viral suppression. However, imperfect ART adherence, even if sufficient maintain suppression, has been associated with adverse clinical outcomes. adherence can be objectively quantified using tenofovir diphosphate (TFV-DP) in dried blood spots (DBS), a biomarker cumulative that is predictive future viremia-even among persons HIV (PWH) an undetectable load...